BIO · Bio-Rad Laboratories, Inc.
$327.02
-3.98 (-1.20%)
At close · Jul 29
Market Cap
$8.86B
Shares
26.76M
Bio-Rad Laboratories, Inc. Earnings Call Transcripts
Every quarterly earnings call for Bio-Rad Laboratories, Inc. (BIO) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼8.9%
$680.80M
−$162.80M
'22 Q3
22-10-27
▼0.3%
$730.30M
$827.70M
'22 Q4
23-02-16
▼3.3%
$676.84M
$69.00M
'23 Q1
23-05-04
▼1.4%
$681.11M
−$1.16B
'23 Q2
23-08-03
▼7.1%
$632.12M
$106.30M
'23 Q3
23-10-26
▼6.7%
$681.20M
$349.70M
'23 Q4
24-02-15
▼9.8%
$610.80M
$383.90M
'24 Q1
24-05-07
▼6.3%
$638.50M
−$2.17B
'24 Q2
24-08-01
▲2.8%
$649.70M
$653.20M
'24 Q3
24-10-30
▼2%
$667.50M
−$715.80M
'24 Q4
25-02-13
▼4.2%
$585.40M
$64.00M
'25 Q1
25-05-01
▲2.1%
$651.60M
$317.80M
'25 Q2
25-07-31
▲0.5%
$653.00M
−$341.90M
'25 Q3
25-10-29
▲3.9%
$693.20M
$720.00M
'25 Q4
26-02-12
LATEST
▲1.1%
$592.10M
−$527.10M
'26 Q1
26-04-30
Earnings call
FY26 · Q2
2026-08-04
Bio-Rad Second Quarter 2026 Earnings Results Conference Call and Webcast
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Jefferies 2026 Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-30
Bio-Rad Laboratories, Inc. Q1 FY2026 Earnings Call
Cautious tone
Middle East Conflict Headwind
Biopharma Stabilization
Digital PCR / QX700 Platform
Revenue
$592.10M
▲ 1.1% YoY Diluted EPS
$-19.55
▼ 953.7% YoY Gross margin
52.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-12
Bio-Rad Laboratories, Inc. Q4 FY2025 Earnings Call
Positive tone
2026 guidance and long-term confidence
Clinical diagnostics segment performance
Gross margin pressure and operational execution
Revenue
$693.20M*
▲ 3.9% YoY Gross margin
49.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-29
Bio-Rad Laboratories, Inc. Q3 FY2025 Earnings Call
Balanced tone
Process chromatography
Clinical Diagnostics and China reimbursement
Geographic performance
Revenue
$653.00M
▲ 0.5% YoY Diluted EPS
$-12.70
▼ 154.4% YoY Gross margin
52.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Bio-Rad Laboratories, Inc. Q2 FY2025 Earnings Call
Positive tone
Process Chromatography Strength
China Diagnostics Reimbursement Pressure
ddPCR Portfolio Expansion
Revenue
$651.60M
▲ 2.1% YoY Diluted EPS
$11.67
Gross margin
53.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Bio-Rad Laboratories, Inc. Q1 FY2025 Earnings Call
Balanced tone
Tariffs and trade tensions
China market dynamics
Academic and government funding headwinds
Revenue
$585.40M
▼ 4.2% YoY Diluted EPS
$2.29
▼ 83% YoY Gross margin
52.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-13
Bio-Rad Laboratories, Inc. Q4 FY2024 Earnings Call
Positive tone
Life Science segment softness
2025 outlook and gradual recovery
China reimbursement change in diabetes testing
Revenue
$667.50M
▼ 2% YoY Diluted EPS
$-25.57
▼ 310.6% YoY Gross margin
51.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Bio-Rad Laboratories, Inc. Q3 FY2024 Earnings Call
Balanced tone
Process Chromatography Destocking
Life Science Market Recovery
Asia Pacific and China Headwinds
Revenue
$649.70M
▲ 2.8% YoY Diluted EPS
$23.34
▲ 541.2% YoY Gross margin
54.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Bio-Rad Laboratories, Inc. Q2 FY2024 Earnings Call
Balanced tone
Life Science demand softness
Clinical diagnostics strength
Process chromatography destocking
Revenue
$638.50M
▼ 6.3% YoY Diluted EPS
$-76.26
Gross margin
55.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Bio-Rad Laboratories, Inc. Q1 FY2024 Earnings Call
Balanced tone
Life Science Market Weakness and Destocking
Clinical Diagnostics Growth
Gross Margin and Cost Actions
Revenue
$610.80M
▼ 9.8% YoY Diluted EPS
$13.45
▲ 479.7% YoY Gross margin
53.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Bio-Rad Laboratories, Inc. Q4 FY2023 Earnings Call
Cautious tone
Life Science and ddPCR weakness
2024 outlook and guidance
Operational and cost management
Revenue
$681.20M
▼ 6.7% YoY Diluted EPS
$12.14
▼ 56.3% YoY Gross margin
53.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-26
Bio-Rad Laboratories, Inc. Q3 FY2023 Earnings Call
Revenue
$632.12M
▼ 7.1% YoY Diluted EPS
$3.64
Gross margin
53.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Bio-Rad Laboratories, Inc. Q2 FY2023 Earnings Call
Revenue
$681.11M
▼ 1.4% YoY Diluted EPS
$-39.59
Gross margin
53.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Bio-Rad Laboratories, Inc. Q1 FY2023 Earnings Call
Revenue
$676.84M
▼ 3.3% YoY Diluted EPS
$2.32
Gross margin
53.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-16
Bio-Rad Laboratories, Inc. Q4 FY2022 Earnings Call
Revenue
$730.30M
▼ 0.3% YoY Diluted EPS
$27.78
Gross margin
54.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-27
Bio-Rad Laboratories, Inc. Q3 FY2022 Earnings Call
Revenue
$680.80M
▼ 8.9% YoY Diluted EPS
$-5.48
▼ 104.2% YoY Gross margin
54.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-28
Bio-Rad Laboratories, Inc. Q2 FY2022 Earnings Call
Revenue
$691.10M
▼ 3.5% YoY Diluted EPS
$-31.05
▼ 202.1% YoY Gross margin
57.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-28
Bio-Rad Laboratories, Inc. Q1 FY2022 Earnings Call
Revenue
$700.06M
▼ 3.7% YoY Diluted EPS
$-112.50
▼ 446.6% YoY Gross margin
57.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-10
Bio-Rad Laboratories, Inc. Q4 FY2021 Earnings Call
Revenue
$732.80M
▼ 7.2% YoY Diluted EPS
$-52.54
▼ 288.9% YoY Gross margin
54.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-28
Bio-Rad Laboratories, Inc. Q3 FY2021 Earnings Call
Revenue
$747.05M
▲ 15.4% YoY Diluted EPS
$130.02
▲ 197.9% YoY Gross margin
58.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Bio-Rad Laboratories, Inc. Q2 FY2021 Earnings Call
Revenue
$715.93M
▲ 33.4% YoY Diluted EPS
$30.41
▼ 5.4% YoY Gross margin
56.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Bio-Rad Laboratories, Inc. Q1 FY2021 Earnings Call
Revenue
$726.80M
▲ 27.1% YoY Diluted EPS
$32.46
▲ 42.9% YoY Gross margin
55.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-11
Bio-Rad Laboratories, Inc. Q4 FY2020 Earnings Call
Revenue
$789.80M
▲ 26.5% YoY Diluted EPS
$27.81
▲ 51.9% YoY Gross margin
58.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-29
Bio-Rad Laboratories, Inc. Q3 FY2020 Earnings Call
Revenue
$647.26M
▲ 15.5% YoY Diluted EPS
$43.64
Gross margin
56.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Bio-Rad Laboratories, Inc. Q2 FY2020 Earnings Call
Revenue
$536.88M
▼ 6.2% YoY Diluted EPS
$32.15
▲ 61.9% YoY Gross margin
54.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Bio-Rad Laboratories, Inc. Q1 FY2020 Earnings Call
Revenue
$571.64M
▲ 3.2% YoY Diluted EPS
$22.72
▼ 20.9% YoY Gross margin
55.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-13
Bio-Rad Laboratories, Inc. Q4 FY2019 Earnings Call
Revenue
$624.50M
▲ 1.2% YoY Diluted EPS
$18.31
Gross margin
52.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
12208
CUSIP
090572207
13F (30d)
121 filings
94 filers
Visit website
Investor relations